[Experience of the use of nebivolol in the treatment of hypertension in postmenopausal women].
Nebivolol was given to 30 hypertensive postmenopausal women as monotherapy (5-10 mg/day) or in combination with hydrochlorothiazide. Clinical effect was achieved in 76.6 and 86.7% of women on mono- and combination therapy, respectively. Hypotensive effect was confirmed by 24-hour blood pressure monitoring. Blood pressure lowering was associated with decrease of total peripheral resistance and regression of left ventricular hypertrophy. Nebivolol appeared to be metabolically neutral and only sporadic adverse effects were registered.
Bart
B Ia
BIa
Benevskaia
V F
VF
Buval'tsev
V I
VI
Boronenkov
G M
GM
D000704:Analysis of Variance; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001578:Benzopyrans / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004983:Ethanolamines / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006852:Hydrochlorothiazide / Q000627:therapeutic use; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D008875:Middle Aged; D000068577:Nebivolol; D017698:Postmenopause / Q000502:physiology*; D016896:Treatment Outcome
D000959:Antihypertensive Agents; D001578:Benzopyrans; D004983:Ethanolamines; D000068577:Nebivolol; D006852:Hydrochlorothiazide